TomoTherapy and Integra Radionics Partner to Develop a Suite of Stereotactic Fixation Products for the Hi-Art® Treatment System

Business Wire, Oct 11, 2007

MADISON, Wis. -- TomoTherapy Incorporated (NASDAQ: TTPY) announced today that it has partnered with Integra Radionics, Inc., a subsidiary of Integra LifeSciences Holdings Corporation (NASDAQ: IART), to develop and distribute the InterFix[TM] radiosurgery kit. The kit includes a suite of fixation products that have been adapted for use in stereotactic procedures using the TomoTherapy([R]) Hi*Art([R])treatment system.

According to Del Coufal, vice president of marketing for TomoTherapy, the InterFix kit complements the Hi*Art treatment system well: "Radionics products are used in cancer centers around the world. With the InterFix kit, their head rings and fixation tools will work seamlessly with our system, adding to the clinical confidence our integrated CT guidance and helical delivery already make possible."

Introduced in 2003, the TomoTherapy Hi*Art treatment system has been accepted for its image-guided, intensity-modulated radiation therapy (IG/IMRT) capabilities. More than 100 cancer centers in 16 countries use the system to treat a range of cancers that were once treated with conventional linear accelerators. Increasingly, clinicians have also used the Hi*Art system for stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT), where high doses of precisely targeted radiation are delivered in a single or a few treatment fractions.

"More and more cancer centers around the world are adopting TomoTherapy's technology," said Christopher von Jako, general manager of Integra Radionics. "As innovators in the field of radiosurgery, it is important for us develop tools for this platform. We're excited about this opportunity."

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy([R]) Hi*Art([R]) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi*Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company completed its initial public offering in May 2007 and its stock is traded on the NASDAQ Global Market under the symbol TTPY. To learn more about TomoTherapy, please visit our Web site at www.TomoTherapy.com

(c)2007 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi*Art and CTrue are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated. InterFix is a trademark of Integra LifeSciences.